Perspective Therapeutics, Inc.
CATX
$3.47
-$0.215-5.84%
AMEX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -44.87% | 5.23% | -30.56% | 33.70% | -10.54% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -44.87% | 5.23% | -30.56% | 33.70% | -10.54% |
| Cost of Revenue | 73.71% | 86.88% | 93.82% | -- | 82.47% |
| Gross Profit | -81.06% | -90.75% | -94.75% | 33.70% | -95.04% |
| SG&A Expenses | 39.81% | 33.41% | 66.92% | 55.90% | 10.57% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 64.51% | 66.35% | 75.56% | 89.54% | 43.00% |
| Operating Income | -68.54% | -67.87% | -78.62% | -91.12% | -46.23% |
| Income Before Tax | -96.17% | -53.72% | -262.51% | -57.98% | -18.22% |
| Income Tax Expenses | -- | -- | -126.72% | -- | -- |
| Earnings from Continuing Operations | -96.17% | -53.72% | -105.78% | -57.98% | -18.22% |
| Earnings from Discontinued Operations | 204.90% | -- | 98.86% | -- | 69.75% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -83.57% | -47.97% | -62.79% | -46.02% | -5.38% |
| EBIT | -68.54% | -67.87% | -78.62% | -91.12% | -46.23% |
| EBITDA | -70.23% | -66.81% | -252.44% | -89.66% | -44.25% |
| EPS Basic | -64.81% | -1.25% | 35.44% | 41.99% | 55.73% |
| Normalized Basic EPS | -76.05% | -5.16% | 38.21% | 37.24% | 50.31% |
| EPS Diluted | -64.81% | -1.25% | -29.56% | 41.99% | 55.73% |
| Normalized Diluted EPS | -76.05% | -5.16% | 38.21% | 37.24% | 50.31% |
| Average Basic Shares Outstanding | 11.38% | 46.15% | 152.15% | 151.75% | 138.04% |
| Average Diluted Shares Outstanding | 11.38% | 46.15% | 152.15% | 151.75% | 138.04% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |